drugset / Trial / NCT01440764
Aerosol Inhalation Treatment for Dyspnea
Phase 1/2
Completed
24 enrolled
Beth Israel Deaconess Medical Center
National Institute of Nursing Research (NINR) · collab
RandomizedCrossoverDouble-blindBasic science
Summary
The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.
Timeline
- Start
- 2011-09
- Primary completion
- 2016-04
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furosemide | Other / unclassified | 15 mg | Inhaled |
| Subject | Furosemide | Other / unclassified | 40 mg | Inhaled |
| Subject | Furosemide | Other / unclassified | 80 mg | Inhaled |
Indications
No indication recorded.